Tech at Polsky
Patients who received adjuvant chemotherapy (green, n=110) and those who did not (orange, n=185) were classified using the clinically approved Mammaprint gene signature (NKI 70) as having a good (NKI70 -) or poor (NKI 70+) prognosis. The poor prognosis patients were further stratified with the invention gene signature (IRDS). IRDS (-) patients have increased sensitivity to chemotherapy, evident in comparing the Kaplan-Meier survival curves of the two treatment groups.
July 23, 2019
Clinical validation (retrospective samples)
Reference ID 05-T-101
Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.